Blue Therapeutics is an early-stage biotechnology company focused on developing potent, non-narcotic painkillers. Using our novel GPCR heterodimer targeting approach, we are able to achieve up to 50x the painkilling potency of morphine, but without addictive side effects. Our lead clinical candidate, BLUE-181, is currently advancing through IND-enabling studies in support of first-in-human clinical trials.


Every day in the U.S. 115 people die from opioid overdose while millions of patients in pain continue to suffer without good therapeutic options. Our mission is to displace current opioids by providing a safe and effective alternative for the treatment of both acute and chronic pain conditions.

Harvard Innovation Launch Lab